The hemophilia A and B markets in the Asia-Pacific (APAC) region are forecast to expand from $444.9 million and $76.3 million in 2015 to $699.1 million and $112.9 million by 2022, representing compound annual growth rates of 6.7% and 5.8%, respectively, according to business intelligence provider GBI Research.
The company’s latest report states that the growing awareness of hemophilia and associated risk factors, together with the availability of free testing services for new and existing hemophilia A and B patients, will increase diagnosis, driving demand and contributing to APAC market growth.
Gayathri Kanika, Analyst for GBI Research, notes: “One of the most pressing unmet needs in the hemophilia space is for a treatment to address inhibitor development, particularly in those with hemophilia B. The late-stage pipeline contains promising long-acting replacement therapies and non-factor therapies that have the potential for approval and launch during the forecast period.”
The most important driver of growth in the APAC hemophilia A and B markets will be the transition from short-acting to costly long-acting replacement therapies, such as Novo Nordisk’s N9-GP and CSL-Behring’s CSL-689. These products are expected to be launched in the forecast period and capture significant market share, as they require fewer injections and have convenient routes of administration.
In addition to new drugs and rising hemophilia diagnoses, increasing affordability and healthcare access in India and China are likely to contribute to the growth of the treatment-receiving pool significantly.
Kanika explains: “Currently, the diagnosis and treatment rates of hemophilia A and B in India and China, which account for the majority of the prevalence population in APAC, are far lower than the diagnosis and treatment rates in Australia, Japan and South Korea, due to low disease awareness among the public. However, some pharma companies, including Baxalta and Novo Nordisk, have created hemophilia awareness initiatives in India.
“In 2016, the National Hemophilia Cooperative Group in China initiated a project that covers 43 hemophilia treatment centers and provides free testing services for new and old hemophiliacs, helping more than 6,000 people with hemophilia.